Your browser doesn't support javascript.
loading
Post-operative re-irradiation with hyperthermia in locoregional breast cancer recurrence: Temperature matters.
Bakker, Akke; Tello Valverde, C Paola; van Tienhoven, Geertjan; Kolff, M Willemijn; Kok, H Petra; Slotman, Ben J; Konings, Inge R H M; Oei, Arlene L; Oldenburg, Hester S A; Rutgers, Emiel J T; Rasch, Coen R N; van den Bongard, H J G Desirée; Crezee, Hans.
Afiliação
  • Bakker A; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: akke.bakker@amsterdamumc.nl.
  • Tello Valverde CP; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: c.p.tellovalverde@amsterdamumc.nl.
  • van Tienhoven G; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: g.vantienhoven@amsterdamumc.nl.
  • Kolff MW; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: m.w.kolff@amsterdamumc.nl.
  • Kok HP; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: h.p.kok@amsterdamumc.nl.
  • Slotman BJ; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: bj.slotman@amsterdamumc.nl.
  • Konings IRHM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: i.konings@amsterdamumc.nl.
  • Oei AL; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amste
  • Oldenburg HSA; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: h.oldenburg@nki.nl.
  • Rutgers EJT; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: e.rutgers@nki.nl.
  • Rasch CRN; Department of Radiation Oncology, LUMC, Leiden, the Netherlands. Electronic address: c.r.n.rasch@lumc.nl.
  • van den Bongard HJGD; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: h.j.vandenbongard@amsterdamumc.nl.
  • Crezee H; Department of Radiation Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: h.crezee@amsteramumc.nl.
Radiother Oncol ; 167: 149-157, 2022 02.
Article em En | MEDLINE | ID: mdl-34973278
ABSTRACT

PURPOSE:

To investigate the impact of hyperthermia thermal dose (TD) on locoregional control (LRC), overall survival (OS) and toxicity in locoregional recurrent breast cancer patients treated with postoperative re-irradiation and hyperthermia.

METHODS:

In this retrospective study, 112 women with resected locoregional recurrent breast cancer treated in 2010-2017 with postoperative re-irradiation 8frx4Gy (n = 34) or 23frx2Gy (n = 78), combined with 4-5 weekly hyperthermia sessions guided by invasive thermometry, were subdivided into 'low' (n = 56) and 'high' TD (n = 56) groups by the best session with highest median cumulative equivalent minutes at 43 °C (Best CEM43T50) < 7.2 min and ≥7.2 min, respectively. Actuarial LRC, OS and late toxicity incidence were analyzed. Backward multivariable Cox regression and inverse probability weighting (IPW) analysis were performed.

RESULTS:

TD subgroups showed no significant differences in patient/treatment characteristics. Median follow-up was 43 months (range 1-107 months). High vs. low TD was associated with LRC (p = 0.0013), but not with OS (p = 0.29) or late toxicity (p = 0.58). Three-year LRC was 74.0% vs. 92.3% in the low and high TD group, respectively (p = 0.008). After three years, 25.0% and 0.9% of the patients had late toxicity grade 3 and 4, respectively. Multivariable analysis showed that distant metastasis (HR 17.6; 95%CI 5.2-60.2), lymph node involvement (HR 2.9; 95%CI 1.2-7.2), recurrence site (chest wall vs. breast; HR 4.6; 95%CI 1.8-11.6) and TD (low vs. high; HR 4.1; 95%CI 1.4-11.5) were associated with LRC. TD was associated with LRC in IPW analysis (p = 0.0018).

CONCLUSIONS:

High thermal dose (best CEM43T50 ≥ 7.2 min) was associated with significantly higher LRC for patients with locoregional recurrent breast cancer treated with postoperative re-irradiation and hyperthermia, without augmenting toxicity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Reirradiação / Hipertermia Induzida Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Reirradiação / Hipertermia Induzida Idioma: En Ano de publicação: 2022 Tipo de documento: Article